Skip to main content

Table 4 Teeth and sites with PPD ≥ 5, ≥ 6 and ≥ 7 mm at baseline, 3- and 6–12 months follow up

From: Clinical effects of probiotic or azithromycin as an adjunct to scaling and root planning in the treatment of stage III periodontitis: a pilot randomized controlled clinical trial

 

Baseline (a)

3 months (b)

12 months (c)

p value (intra-group)

Post-hoc (Bonferroni adjustment)

Effect size (∆3 months-BL)a

Effect size (∆12 months-BL)b

∆3 months-BL

∆12 months-BL

Teeth with PPD ≥ 5 mm (%)

         

Probiotic group (n = 16)

33.3 ± 25.3

13.9 ± 12.5

9.7 ± 10.5

0.0040

a > b (p = 0.0009)

− 0.7 ± 0.7

− 0.9 ± 0.8

− 19.4 ± 18.1

− 23.5 ± 21.6

     

a > c (p = 0.0008)

    

Antibiotic group (n = 16)

42.3 ± 24.1

12.7 ± 11.7

11.6 ± 11.6

0.0008

a > b (p = 0.0007)

− 1.1 ± 0.6

− 1.1 ± 0.7

− 28.5 ± 16.0

− 30.7 ± 18.9

     

a > c (p = 0.0005)

    

Placebo group (n = 15)

46.4 ± 32.6

15.0 ± 21.1

15.2 ± 19.1

0.0034

a > b (p = 0.0007)

− 1.2 ± 0.9

− 1.2 ± 0.9

− 31.4 ± 25.3

− 31.2 ± 23.8

     

a > c (p = 0.0008)

    

p value (inter-group)

0.4163

0.8307

0.8075

    

0.1978

0.4069

Teeth with PPD ≥ 6 mm (%)

         

Probiotic group (n = 16)

15.9 ± 15.4

6.4 ± 7.3

4.9 ± 6.2

0.0184

a > b (p = 0.0165)

− 0.5 ± 0.7

− 0.6 ± 0.7

− 9.6 ± 12.6

− 11.1 ± 13.8

     

a > c (p = 0.0089)

    

Antibiotic group (n = 16)

16.7 ± 12.6

6.4 ± 8.2

5.5 ± 8.1

0.0014

a > b (p = 0.0009)

− 0.5 ± 0.5

− 0.6 ± 0.5

− 10.2 ± 8.8

− 11.2 ± 9.0

     

a > c (p = 0.0007)

    

Placebo group (n = 15)

26.6 ± 25.8

8.4 ± 13.7

8.5 ± 12.2

0.0054

a > b (p = 0.0025)

− 1.0 ± 0.9

− 1.0 ± 1.0

− 18.2 ± 7.6

− 18.2 ± 18.4

     

a > c (p = 0.0043)

    

p value (inter-group)

0.6056

0.9650

0.6213

    

0.3702

0.2921

Teeth with PPD ≥ 7 mm (%)

         

Probiotic group (n = 16)

8.3 ± 11.0

2.3 ± 2.9

1.8 ± 2.6

0.0490

a > b (p = 0.0738)

− 0.4 ± 0.7

− 0.5 ± 0.7

− 6.0 ± 9.7

− 6.5 ± 9.2

     

a > c (p = 0.0145)

    

Antibiotic group (n = 16)

7.6 ± 7.6

3.0 ± 5.2

2.4 ± 4.7

0.0049

a > b (p = 0.0015)

− 0.4 ± 0.4

− 0.4 ± 0.5

− 5.1 ± 5.5

− 5.2 ± 7.1

     

a > c (p = 0.0077)

    

Placebo group (n = 15)

16.1 ± 19.7

5.7 ± 8.9

5.1 ± 6.9

0.0469

a > b (p = 0.0122)

− 0.7 ± 0.9

− 0.8 ± 1.1

− 10.4 ± 13.1

− 11.0 ± 14.7

     

a > c (p = 0.0143)

    

p value (inter-group)

0.6573

0.8204

0.3481

    

0.6055

0.8091

Sites with PPD ≥ 5 mm (%)

         

Probiotic group (n = 16)

10.9 ± 10.2

3.4 ± 3.6

2.4 ± 2.9

0.0043

a > b (p = 0.0013)

− 0.6 ± 0.6

− 0.7 ± 0.7

− 7.6 ± 7.9

− 8.5 ± 9.1

     

a > c (p = 0.0011)

    

Antibiotic group (n = 16)

14.1 ± 8.9

3.6 ± 4.3

3.3 ± 4.0

0.0005

a > b (p = 0.0007)

− 0.8 ± 0.4

− 0.8 ± 0.5

− 10.2 ± 5.7

− 10.8 ± 6.6

     

a > c (p = 0.0005)

    

Placebo group (n = 15)

20.0 ± 18.6

4.8 ± 7.2

4.3 ± 6.1

0.0019

a > b (p = 0.0007)

− 1.1 ± 1.1

− 1.2 ± 1.1

− 15.2 ± 14.6

− 15.7 ± 14.9

     

a > c (p = 0.0007)

    

p value (inter-group)

0.3755

0.8940

0.8700

    

0.2328

0.3160

Sites with PPD ≥ 6 mm (%)

         

Probiotic group (n = 16)

4.3 ± 4.7

1.4 ± 1.7

1.2 ± 2.0

0.0180

a > b (p = 0.0215)

− 0.4 ± 0.5

− 0.4 ± 0.5

− 2.9 ± 3.7

− 3.1 ± 4.1

     

a > c (p = 0.0076)

    

Antibiotic group (n = 16)

4.9 ± 4.4

1.6 ± 2.7

1.3 ± 2.1

0.0049

a > b (p = 0.0009)

− 0.4 ± 0.3

0.4 ± 0.4

− 3.5 ± 2.6

− 3.6 ± 3.6

     

a > c (p = 0.0017)

    

Placebo group (n = 15)

10.2 ± 11.3

2.2 ± 3.5

2.1 ± 3.1

0.0013

a > b (p = 0.0030)

− 1.0 ± 1.1

− 1.0 ± 1.2

− 8.0 ± 9.1

− 8.1 ± 9.3

     

a > c (p = 0.0011)

    

p value (inter-group)

0.4818

0.9371

0.6105

    

0.3637

0.4272

Sites with PPD ≥ 7 mm (%)

         

Probiotic group (n = 16)

1.8 ± 2.6

0.6 ± 1.0

0.6 ± 1.4

0.0407

a > b (p = 0.0738)

− 0.3 ± 0.5

− 0.3 ± 0.5

− 1.2 ± 1.9

− 1.2 ± 1.9

     

a > c (p = 0.0195)

    

Antibiotic group (n = 16)

1.9 ± 2.1

0.6 ± 1.3

0.6 ± 1.2

0.0042

a > b (p = 0.0016)

− 0.4 ± 0.4

− 0.3 ± 0.4

− 1.4 ± 1.6

− 1.4 ± 1.7

     

a > c (p = 0.0043)

    

Placebo group (n = 15)

4.7 ± 6.8

1.4 ± 2.4

1.1 ± 1.8

0.0423

a > b (p = 0.0198)

− 0.8 ± 1.4

− 0.9 ± 1.5

− 3.3 ± 5.5

− 3.6 ± 6.0

     

a > c (p = 0.0169)

    

p value (inter-group)

0.5671

0.8492

0.4180

    

0.5396

0.7226

  1. Note: Data presented as mean ± SD of percentages. BL baseline, PPD probing pocket depth
  2. aEffect size of (∆3 months‐BL) was calculated by delta mean change from month 3 to baseline over standard deviation of baseline. bEffect size of (∆12 months‐BL) was calculated by delta mean change from month 12 to baseline over standard deviation of baseline
  3. Intra-group comparison by Friedman test (p < 0.05) and Bonferroni-corrected Wilcoxon signed rank test (p < 0.025). Statistical significant in bold
  4. Inter-group comparison by ANOVA and Kruskal Wallis test (p < 0.05)